Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BR790 + Anlotinib in Advanced NSCLC
NCT05715398Phase 2Not yet recruiting
- Sponsor
- Shanghai Gopherwood Biotech
- Start
- Feb 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of BR790 in non-small cell lung cancer (NSCLC), sponsored by Shanghai Gopherwood Biotech. Primary endpoints: Maximum Tolerated Dose / Recommended Phase 2 Dose at 2 years and Objective Response Rate at 2 years. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
BR790
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05715398.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05715398.